GlassScriptPhysician profile
Raymond Kidwell
NPI 1801978457
$2,728.48
in general payments reported to CMS, 2019-2025
16 companies · $604 in 2025
The $604 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $203 · 2021: $223 · 2022: $615 · 2023: $400 · 2024: $521 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,501 · Education: $24.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,501.15 |
| Education | $24.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $367.94 | 2019-2025 | |
| Janssen Biotech, INC. | $365.49 | 2019-2025 | Tremfya, Remicade, Simponi Aria |
| Incyte Corporation | $306.67 | 2021-2025 | Opzelura, Iclusig |
| Galderma Laboratories, L.P. | $274.38 | 2019-2025 | Nemluvio, Aklief |
| Pfizer INC. | $265.32 | 2022-2025 | |
| Amgen INC. | $212.05 | 2021-2025 | Otezla, Otezla |
| Leo Pharma INC. | $200.41 | 2022-2025 | Adbry, Anzupgo |
| Biofrontera INC. | $144.84 | 2019-2025 | Ameluz, Rhodoled Xl, Bf-Rhodoled |
| Novartis Pharmaceuticals Corporation | $137.32 | 2024-2025 | |
| Ucb, INC. | $136.80 | 2024 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $122.10 | 2021-2024 | Dupixent |
| Genzyme Corporation | $64.70 | 2021-2023 | |
| Almirall LLC | $51.02 | 2021-2023 | Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.98 | 2020-2023 | Duobrii, Arazlo, Jublia |
| Sun Pharmaceutical Industries INC. | $20.46 | 2023 | Blu-U |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $18.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Kidwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.